Julio-Septiembre 2018 N°75
ISSN 1317-987X
 
Buscar




Artículos
 
Adherencia al tratamiento farmacológico para la diabetes e hipertensión en sujetos de dos comunidades del Municipio Sucre. Estado Miranda. Venezuela
Introducción
Metodología
Resultados
Discusión
Conclusión
Bibliografía



Bioquímica
Adherencia al tratamiento farmacológico para la diabetes e hipertensión en sujetos de dos comunidades del Municipio Sucre. Estado Miranda. Venezuela

Bibliografía

  1. Vrijens B, De Geest S, Hughes DA,  Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, ABC Project Team. A new taxonomy for describ¬ing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691–705.
  2. Dilla T,  Valladares A,  Lizán L, Sacristan J. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora. Aten Primaria. 2009; 41(6):342–348.
  3. De Geest S, Sabaté E. Adherence to long term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003; 2(4):323.
  4. Nilsson JLG, Andersson K, Bergkvist A, Bjorkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl). 2006; 15(3):235–237.
  5. Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence. 2013; 7:675-682.
  6. Bhupathiraju SN, Hu FB. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circ Res 2016; 118(11):1723-1735.
  7. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks and clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(10010):2287-2323.
  8. Kolandaivelu K, Leiden BD, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014; 35:3267-3276.
  9. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. JHumHypertens.2014;28:463–468.
  10. Calhoun DA, Booth 3rd JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014; 63:451–458.
  11. Gupta P, Patel P, Horne R, Buchanan H, Williams B, Tomaszewski M. How to Screen for Non-Adherence to Antihypertensive Therapy. Curr Hypertens Rep. 2016; 18(12):89.
  12. O'Donnell M, Mente A, Yusuf S. Sodium intake and cardiovascular health. Circ Res. 2015; 116(6):1046-1057.
  13. Flores L, Vidal J, Núñez I, Rueda S, Viaplana J, Esmatjes E. Longitudinal changes of blood pressure after weight loss: factors involved. Surg Obes Relat Dis. 2015; 11(1):215-221
  14. Roerecke M, Kaczorowski J, Tobe S, Gmel G,Hasan O,  Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017; 2: e108–120.
  15. Millar P, Goodman JM. Exercise as medicine: role in the management of primary hypertension Appl Physiol Nutr Metab. 2014; 39(7):856-858.
  16. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 2014; 311(5):507-520.
  17. International Diabetes Federation (IDF). IDF Diabetes Atlas. 7th ed. 2015. Consultado el 15 de Septiembre de 2017. Disponible en: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.
  18. Polonsky WH, Henry RR.  Poor medication adherence in type 2 diabetes: recognizing the scope of the problema and its key. Patient Prefer Adherence. 2016; 10:1299-1307.
  19. Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, Mauldin PD. Medication nonadher¬ence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012; 35(12):2533–2539.
  20. Di Bonaventura M, Wintfeld N, Huang J, Goren A. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient Prefer Adherence. 2014; 8:873–882.
  21. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabe¬tes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87.
  22. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persis¬tence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther. 2014; 31(12):1287–1305.
  23. Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015; 32(6):725–737.
  24. Gomes-Villa L, Soares M, Pace A. Adherence to treatment for Diabetes Mellitus: validations of instruments for oral  antidiabetics and insulin. Rev Lat Am Enfermagem. 2014; 22(1): 11–18.
  25. American Diabetes Association. Standards of Medical Care in Diabetes 2017. Diabetes Care 2017; 40(1): S6-S10.
  26. Moncrieft A,  Llabre M,  Rey J, Gutt M, Mendez A,  Gellman M, Goldberg R,  Schneiderman N. Effects of a Multicomponent Life-Style Intervention on Weight, Glycemic Control, Depressive Symptoms, and Renal Function in Low-Income, Minority Patients With Type 2 Diabetes. Results of The Community Approach to Lifestyle Modification for Diabetes Randomized Controlled Trial. Psychosom Med. 2016; 78(7): 851–860.
  27. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012; 35(4):731-737
  28. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5):323-329.
  29. Ford RJ, Fullerton MD, Pinkosky SL, Day EA, Scott JW, Oakhill JS, Bujak AL, Smith BK, Crane JD, Blümer RM, Marcinko K, Kemp BE, Gerstein HC, Steinberg GR. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J.2015; 468(1):125-132.
  30. Esteghamati A, Eskandari D, Mirmiranpour H, Noshad S, Mousavizadeh M, Hedayati M, Nakhjavani M. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr. 2013; 32(2):179-185.
  31. Derosa, G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF. Candesartan effect on inflammation in hypertension. Hypertens Res. 2010; 33(3):209-213.
  32. Komoda, H., T. Inoue,  K. Node, Anti-inflammatory properties of azelnidipine, a dihydropyridine- based calcium channel blocker. Clin Exp Hypertens, 2010; 32(2):   121-128
  33. Vasigar P, Batmanabane M. Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013; 4(4):238-242.
  34. Marulanda M. Estudio de las prácticas en manejo de la diabetes en Venezuela (IDMPS-Venezuela Ola 2). Med Interna (Caracas). 2012; 28(4): 214-222.
  35. Martínez G, Martínez L, Rodríguez M, Agudelo C, Jiménez J, Vargas N, Lopera J. Adherencia terapéutica y control metabólico en pacientes con diabetes mellitus tipo 2 pertenecientes a una institución hospitalaria de la ciudad de Medellin (Colombia), año 2011. Archivos de Medicina (Col.). 2014; 14(1): 44-50.
  36. Iglay K, Cartier SE, Rosen VM, Zarotsky V, Rajpathak SN, Radican L, Tunceli K. Metanalysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015; 31(7):1283-1296
  37. Terechenco N, Baute A, Zamonsky J. Adherencia al tratamiento en pacientes con diagnóstico de Diabetes Mellitus Tipo II. Biomedicina 2015; 10 (1): 20-33.
  38. Nogués X, Sorli, M, Villar J. Instrumentos de medida de adherencia al tratamiento. An Med Interna (Madrid). 2007; 24 (3): 138-141.
  39. Shakil-Ur-Rehman S, Karimi H, Gillani SA. Effects of supervised structured aerobic exercise training program on fasting blood glucose level, plasma insulin level, glycemic control, and insulin resistance in type 2 diabetes mellitus. Pak J Med Sci. 2017; 33(3):576-580.
  40. Larsen JJ, Dela F, Madsbad S, Vibe-Petersen J, Galbo H. Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients. Diabetes Care. 1999; 22(10):1647-1654.
  41. Colberg SR, Sigal RJ, Yardley JE, Riddle MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care 2016; 39:2065-2079.
  42. Casas M, Montoya D. ¿Son fiables los medidores de glucemia capilar? Av Diabetol 2012; 28(5): 110-113.
  43. Somannavar S, Ganesan A, Deepa M, Datta M, Mohan V. Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India. Diabetes Care 2009; 32(4):641-643.
  44. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including newdrugsand 2-drugcombinations. Ann Intern Med 2011; 154:602–613.
  45. Herrera E. Adherencia al tratamiento en personas con hipertensión arterial. Av. Emferm.2012; 30(2): 67-75.
  46. Bermúdez V, Rojas J, Añez R, Lopez J. Prevalence, awareness, management of hypertension and association with metabolic abnormalities: the Maracaibo city metabolic syndrome prevalence study. Rev Lat Hipert 2012; 7(4):71-79.
  47. Rojas M, Rosales Y, Guerrero N, Morillo J, Añez R, Bermúdez V, Rojas J. Comportamiento epidemiológico de la hipertensión arterial en individuos adultos del Municipio San Cristóbal del Estado Táchira. Venezuela. Rev Lat Hipert 2016; 11(1): 1-11.
  48.  Fox C, Massaro J, Hoffmann U,    Pou K,  Maurovich-Horvat P,  Liu C,   Vasan R, Murabito M,   Meigs  J, Cupples A, D’Agostino R,  O’Donnell C. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments. Association with Metabolic Risk Factors in the Framingham Heart Study. Circulation 2007; 116:39-48.
Adherencia al tratamiento farmacológico para la diabetes e hipertensión en sujetos de dos comunidades del Municipio Sucre. Estado Miranda. Venezuela
Introducción
Metodología
Resultados
Discusión
Conclusión
Bibliografía

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit